Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Chicago
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000262

Purpose

The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Nitrous oxide	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Effects of Combined Sevoflurane and Nitrous Oxide Inhalation

Resource links provided by NLM:

Drug Information available for: Sevoflurane Nitrous oxide

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Pain intensity, pain bothersomeness
Mood
Psychomotor performance

Estimated Enrollment:	0
Study Start Date:	November 1996

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000262

Locations

United States, Illinois
University of Chicago, Anesthesia & Critical Care
Chicago, Illinois, United States, 60637

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Chicago

Investigators

Principal Investigator:

James Zacny, Ph.D.

University of Chicago

More Information

No publications provided

Study ID Numbers:	NIDA-08391-14, R01-08391-14
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000262 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Disease
Nitrous Oxide
Hematologic Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Anesthetics
Disorders of Environmental Origin
Opioid-Related Disorders
Pharmacologic Actions
Sevoflurane
Anesthetics, Inhalation

Pathologic Processes
Anesthetics, General
Mental Disorders
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Substance-Related Disorders
Platelet Aggregation Inhibitors
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009